Alendronate decreases contractile responses by affecting ATP-sensitive potassium channels in human left internal mammary artery rings

Basit Öğe Kaydı
dc.contributor.authorArun M.Z.
dc.contributor.authorReel B.
dc.contributor.authorGuzeloglu M.
dc.contributor.authorAlbayrak G.
dc.contributor.authorAykut K.
dc.contributor.authorHazan E.
dc.date.accessioned2019-10-27T08:22:25Z
dc.date.available2019-10-27T08:22:25Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractBisphosphonates, including alendronate, are widely used for the treatment of osteoporosis, hypercalcemia and bone metastasis associated with cancer. However, recent evidence has demonstrated anti-atherosclerotic effects of bisphosphonates in animal models and atherosclerotic patients. Besides, some studies have shown that bisphosphonates change calciwn homeostasis in cardiomyocytes and interfere L-type calciwn chmels in vascular smooth muscle cells. Therefore, in the present study it was aimed to investigate the effects of alendronate on contractile responses and ATP-sensitive potassiwn channels in vitro in hwnan Left Internal Mammary Artery (LIMA). Hwnan LIMA rings were placed into isolated organ chambers. After resting period, rings were kept for an hour in incubation mediwn which contains alendronate (10-6 M) or not (control) and responses of the rings to the contractile agents were examined. The incubation of two rings was performed in the presence of glibenclamide which is ATP-sensitive potassiwn channel blocker (10-6M). Maximwn contractile responses of LIMA rings to noradrenalin and serotonin decreased in the presence of alendronate. In concomitant incubation of LIMA with alendronate and glibenclamide reversed decreased contractions to noradrenalin or serotonin caused by alendronate. However, neither alendronate nor glibenclamide changed sensitivity to noradrenaline or serotonin. The present findings point out that alendronate may change intracellular calciwn dynamics in hwnan LIMA, due to the activation of ATP-sensitive potassiwn channels which have an important role on cardiovascular system. © 2014 Asian Network for Scientific Informationen_US
dc.identifier.doi10.3923/ijp.2014.501.506
dc.identifier.endpage506en_US
dc.identifier.issn1811-7775
dc.identifier.issn1811-7775en_US
dc.identifier.issue8en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage501en_US
dc.identifier.urihttps://doi.org/10.3923/ijp.2014.501.506
dc.identifier.urihttps://hdl.handle.net/11454/26248
dc.identifier.volume10en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAsian Network for Scientific Informationen_US
dc.relation.ispartofInternational Journal of Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAlendronateen_US
dc.subjectBisphosphonatesen_US
dc.subjectContractionen_US
dc.subjectLIMAen_US
dc.subjectPotassiwn channelsen_US
dc.titleAlendronate decreases contractile responses by affecting ATP-sensitive potassium channels in human left internal mammary artery ringsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu